Biology and Treatment of Human Myeloid Cancers

人类骨髓癌的生物学和治疗

• 批准号: MC_UU_00029/8
• 负责人: Paresh Vyas
• 金额: $ 319.44万
• 依托单位: University of Oxford
• 依托单位国家: 英国
• 项目类别: Intramural
• 财政年份: 2022
• 资助国家: 英国
• 起止时间: 2022 至 无数据
• 项目状态: 未结题
• 来源: https://gtr.ukri.org/projects?ref=MC_UU_00029%2F8
• 关键词: Biology; Treatment; Human; Myeloid; Cancers

Blood cancers are the 5th most common cancers. This program studies the biology of the most common aggressive adult leukemia, acute myeloid leukemia and blood disorders related to it. The programme is tracing these cancers from the first events that establish the foundations for these cancers to develop late in life, to the events that lead to fully formed cancers. The programme is also to devlope new treatments that harms the power of the immune sustem to cure these cancers.

血癌是第五大常见癌症。该项目研究最常见的侵袭性成人白血病、急性髓细胞白血病及其相关血液疾病的生物学。该项目追踪这些癌症从最初的事件（为这些癌症在生命后期发展奠定基础）到导致完全形成癌症的事件。该计划还将开发新的治疗方法，以损害免疫系统治愈这些癌症的能力。

项目成果

AML-432 Overall Survival (OS) by Mutant Allele (R140 or R172) in Patients With Late-Stage, Mutant- Relapsed/Refractory Acute Myeloid Leukemia (AML) Treated With Enasidenib or Conventional Care Regimens (CCR) in the Randomized, Open-Label, Phase 3 IDHENTIFY Trial

AML-432 突变等位基因（R140 或 R172）在随机、开放性研究中接受 Enasidenib 或常规治疗方案 (CCR) 治疗的晚期、突变复发/难治性急性髓系白血病 (AML) 患者的总生存 (OS)

• DOI: 10.1016/s2152-2650(22)01293-9
• 发表时间: 2022
• 期刊: Clinical Lymphoma Myeloma and Leukemia
• 影响因子: 2.7
• 作者: DiNardo C

TP53-Mutated Myelodysplastic Syndrome and Acute Myeloid Leukemia: Biology, Current Therapy, and Future Directions.

• DOI: 10.1158/2159-8290.cd-22-0332
• 发表时间: 2022-11-02
• 期刊: CANCER DISCOVERY
• 影响因子: 28.2
• 作者: Daver, Naval G.;Maiti, Abhishek;Kadia, Tapan M.;Vyas, Paresh;Majeti, Ravindra;Wei, Andrew H.;Garcia-Manero, Guillermo;Craddock, Charles;Sallman, David A.;Kantarjian, Hagop M.
• 通讯作者: Kantarjian, Hagop M.

Tolerability and Efficacy of the Anticluster of Differentiation 47 Antibody Magrolimab Combined With Azacitidine in Patients With Previously Untreated AML: Phase Ib Results.

分化抗体的耐受性和疗效47抗体Magrolimab与阿扎西替丁在先前未经治疗的AML：IB期结果的患者中结合使用。

• DOI: 10.1200/jco.22.02604
• 发表时间: 2023-11-01
• 期刊: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Enasidenib vs conventional care in older patients with late-stage mutant-IDH2 relapsed/refractory AML: a randomized phase 3 trial.

• DOI: 10.1182/blood.2021014901
• 发表时间: 2023-01-12
• 期刊: BLOOD
• 影响因子: 20.3
• 作者: de Botton, Stephane;Montesinos, Pau;Schuh, Andre C.;Papayannidis, Cristina;Vyas, Paresh;Wei, Andrew H.;Ommen, Hans;Semochkin, Sergey;Kim, Hee-Je;Larson, Richard A.;Koprivnikar, Jaime;Frankfurt, Olga;Thol, Felicitas;Chromik, Joerg;Byrne, Jenny;Pigneux, Arnaud;Thomas, Xavier;Salamero, Olga;Vidriales, Maria Belen;Doronin, Vadim;Doehner, Hartmut;Fathi, Amir T.;Laille, Eric;Yu, Xin;Hasan, Maroof;Martin-Regueira, Patricia;DiNardo, Courtney D.
• 通讯作者: DiNardo, Courtney D.

MDS-482 Impact Of Magrolimab in Combination With Azacitidine on Red Blood Cells (RBCs) in Patients With Higher-Risk Myelodysplastic Syndromes (HR MDS)

MDS-482 Magrolimab 联合阿扎胞苷对高危骨髓增生异常综合征 (HR MDS) 患者红细胞 (RBC) 的影响

• DOI: 10.1016/s2152-2650(22)01421-5
• 发表时间: 2022
• 期刊: Clinical Lymphoma Myeloma and Leukemia
• 影响因子: 2.7
• 作者: Chen J